This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shi, R.
Right arrow Articles by Sugawara, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, R.
Right arrow Articles by Sugawara, I.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2007, p. 4515-4517, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00416-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Lack of Correlation between embB Mutation and Ethambutol MIC in Mycobacterium tuberculosis Clinical Isolates from China{triangledown}

Ruiru Shi,1,2 Jianyuan Zhang,3 Koji Otomo,1 Guolong Zhang,2 and Isamu Sugawara1*

Mycobacterial Reference Center, The Research Institute of Tuberculosis, Tokyo, Japan,1 Henan Provincial Chest Hospital, Zhengzhou, China,2 Beijing Tuberculosis and Lung Tumor Research Institute, Beijing, China3

Received 26 March 2007/ Returned for modification 22 May 2007/ Accepted 2 September 2007

Seventy-four Mycobacterium tuberculosis clinical isolates from China were subjected to drug susceptibility testing using ethambutol, isoniazid, rifampin, and ofloxacin. The results revealed that the presence of embB mutations did not correlate with ethambutol resistance but was associated with multiple-drug resistance, especially resistance to both ethambutol and rifampin.


* Corresponding author. Mailing address: Mycobacterial Reference Center, The Research Institute of Tuberculosis, 3-1-24 Matsuyama, Kiyose, Tokyo 204-0022, Japan. Phone: 81 42 493 5075. Fax: 81 42 492 4600. E-mail: sugawara{at}jata.or.jp

{triangledown} Published ahead of print on 10 September 2007.


Antimicrobial Agents and Chemotherapy, December 2007, p. 4515-4517, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00416-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Starks, A. M., Gumusboga, A., Plikaytis, B. B., Shinnick, T. M., Posey, J. E. (2009). Mutations at embB Codon 306 Are an Important Molecular Indicator of Ethambutol Resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 53: 1061-1066 [Abstract] [Full Text]  
  • Safi, H., Sayers, B., Hazbon, M. H., Alland, D. (2008). Transfer of embB Codon 306 Mutations into Clinical Mycobacterium tuberculosis Strains Alters Susceptibility to Ethambutol, Isoniazid, and Rifampin. Antimicrob. Agents Chemother. 52: 2027-2034 [Abstract] [Full Text]